Eli Lilly and Co. plans to streamline operations that will result in global workforce reductions impacting approximately 3,500 positions. The company expects annual savings of approximately $500 million that will begin to be realized in 2018. Lilly expects the majority of the positions eliminated to come from a U.S. voluntary early retirement program. The program will be mostly complete by December 31, 2017.
Remaining positions will come from other anticipated workforce reductions, including select site closures. The company will move production from its animal health manufacturing facility in Larchwood, IA, to an existing plant in Fort Dodge, IA. In addition, an R&D office in Bridgewater, NJ, and the Lilly China R&D Center in Shanghai will close.
"We have an abundance of opportunities—eight medicines launched in the past four years and the potential for two more by the end of next year," said David A. Ricks, Lilly's chairman and chief executive officer. "To fully realize these opportunities and invest in the next generation of new medicines, we are taking action to streamline our organization and reduce our fixed costs around the world. The actions will result in a leaner, more nimble global organization and will accelerate progress towards our long-term goals of growing revenue, expanding operating margins and sustaining the flow of life-changing medicines from our pipeline."
Breaking News
Lilly Restructures
To cut global workforce by approximately 3,500
09.08.17
Related Breaking News
-
Promotions & Moves
-
Collaborations & Alliances
Infinity, BMS Expand PI3K-gamma Clinical Collaboration
IPI-549 in combination with Opdivo to include patients with triple negative breast cancer09.25.17
-
Promotions & Moves
Sarepta Therapeutics Appoints CSO
Basi to lead the direction of the company’s discovery pipeline and translational research efforts09.25.17
-
Clinical Trial Materials | Industry News
VWR Opens New Kitting Cetner in Czech Republic
New facility will support the Therapak business for clinical trial, pharmaceutical and clinical lab industries09.25.17
-
Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Facilities | Process Development | Scale-up/ Technology Transfer
ADC Bio Invests $11M in Bioconjugation Facility
Will provide capabilities and R&D technical services from process development through to manufacturing09.25.17
-
Industry News
LabCentral, Pfizer to Open Next-Stage Facility
New, 33,000-sq.-ft. lab will house as many as six early- to mid-stage companies09.21.17
-
Trials & Filings
EU Approves Merck KGaA and Pfizer's BAVENCIO
Monotherapy to treat metastatic Merkel cell carcinoma, a rare and aggressive skin cancer09.21.17
-
Promotions & Moves
Envigo Makes Executive Appointments
Boyd to serve as chief commercial officer, Muller to head EMEA operations09.21.17
-
Breaking News | Cold Chain Management | Facilities | Industry News | Packaging & Tracking
PCI Expands Cold Chain Capacity
Investment in Philadelphia site is a considerable expansion of onsite cold chain storage09.20.17
-
Breaking News | Industry News | Packaging & Tracking | Solid Dosage / Semi-solids
Tjoapack Invests in Bottle Packing Ops
Dutch contract packager capable of process 13,000 tablets per minute09.20.17
-
Breaking News | Facilities | Industry News | Solid Dosage/ Creams/ Ointments
Recipharm, Roche Sign Long-term Mfg. Deal
CDMO to manufacture solid dose products and acquires facility in Spain09.20.17
-
Breaking News | Industry News | Packaging & Tracking | Promotions & Moves | Serialization
Supply Chain Wizard Grows Global Footprint
Opens new UK-Ireland office in London, and Latin American office in Miami09.20.17
-
cGMP Manufacture | Fill/Finish | Industry News
Catalent to Acquire Cook Pharmica for $950M
Expands biologics development and analytical services, manufacturing, and finished product supply09.19.17
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
-
Breaking News | Capsules | cGMP Manufacture | Collaborations & Alliances | Industry News | Solid Dosage/ Creams/ Ointments
Recipharm, Kancera in CTM Alliance
Development and manufacture of drug candidate KAND567 to take place in Solna, Sweden09.18.17
